about
Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF)Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver diseaseReproductive status is associated with the severity of fibrosis in women with hepatitis C.Serum γ-glutamyl transferase levels, insulin resistance and liver fibrosis in patients with chronic liver diseasesBoceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.NT pro BNP plasma level and atrial volume are linked to the severity of liver cirrhosis.PNPLA3 GG genotype and carotid atherosclerosis in patients with non-alcoholic fatty liver disease.Hepatitis C and diabetes: the inevitable coincidence?How to optimize HCV therapy in genotype 1 patients: predictors of response.Cardiovascular diseases and HCV infection: a simple association or more?Current and future HCV therapy: do we still need other anti-HCV drugs?Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study.Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD.Insulin-like growth factor-I, inflammatory proteins, and fibrosis in subjects with nonalcoholic fatty liver disease.Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease.Comparison of Histochemical Staining Methods and Correlation with Transient Elastography in Acute Hepatitis.TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C.Fibrosis evaluation by transient elastography in patients with long-term sustained HCV clearance.PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C.Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C.Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.Body mass index and liver stiffness affect accuracy of ultrasonography in detecting steatosis in patients with chronic hepatitis C virus genotype 1 infection.Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients.Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1.Liver follicular helper T-cells predict the achievement of virological response following interferon-based treatment in HCV-infected patients.Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection.Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis c virus genotype 1.Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C.Methylenetetrahydrofolate reductase homozygosis and low-density lipoproteins in patients with genotype 1 chronic hepatitis C.Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection.Effects of IL28B rs12979860 CC genotype on metabolic profile and sustained virologic response in patients with genotype 1 chronic hepatitis C.High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C.Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients.Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C.Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C.TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1.Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C.Inverse correlation between plasma oxysterol and LDL-cholesterol levels in hepatitis C virus-infected patients.
P50
Q26865724-B6EFA8EF-FBD3-4BD7-9C67-75D5BCE75ACAQ28539434-1E88A33E-476F-46A2-8AA5-0E28274718B6Q34412627-76449FF3-C399-4925-9E8F-E75907B98544Q34507283-1D75AD0C-DBA9-4DEC-9D26-2637FED836E5Q34589830-9E416836-5343-4D30-BC6F-6E1987A81494Q34934407-D6393972-75B1-497B-8675-25DBBE0E318FQ34998991-CCFCC841-F974-4698-8E37-75063203F385Q37432092-D509D381-2096-4157-B33F-762F5BAAFE63Q38071384-416B0FFE-F3A9-4E57-B324-C1B6B07751B0Q38167953-D0A024C6-C54C-4C6D-8C1A-C66175F7A500Q38295798-931E9725-E2D4-487F-83A3-938504632F3FQ38632730-946123EB-E5DC-47E3-981A-7D826D5621C8Q38655966-D6C5D77B-3F51-418B-9A3F-823988AF2548Q39211194-527BEA79-65DA-44E3-A57E-019A26A05900Q39352464-94E0BBF2-639C-41B4-AF76-E4BF1354F309Q39724638-EDA0BC0D-7D5A-423B-ABDF-7E417DA055A7Q40263158-330E914B-D9BE-4AEB-ABEA-58CE9678267AQ41498105-A062E70D-9BD2-4DAA-967C-4F0D5CFBCC6EQ41870626-C24A5616-9330-4CE1-9BB1-7F08BD5A3CA0Q42153080-226C3368-BFC1-4230-B08C-8D4951CAAD9DQ42219495-7755E1B4-5E87-4BE4-B21A-5C9E25AC3504Q42227512-D319CC04-E23C-4686-B78B-E88B340C21E0Q42263546-BFF2B221-8E7F-4886-BB47-5D5F2342C1B7Q42277664-EC87C2F7-83E6-41DC-AB9F-1A2FAD183706Q42924276-B9DB7A65-7ABC-42E3-8F19-8B6094E09BD7Q42977052-0CD9950E-4E5D-4BE6-A4CB-45B30CE9EDBBQ42978401-67F4E84B-E2B5-4A90-823B-FF4A01ADC062Q42978681-91390741-5BAC-46B1-9E8E-8A057151DA7FQ42979394-45CF601E-E110-4DEF-8FA5-C2C4B2559FFEQ42981002-67DBCDA3-F319-4BE8-8692-5003077CE442Q42981990-29E8E2E1-6081-49F2-9B04-04A07DAC5645Q42987060-74F5C9EE-F7B2-49D5-A3EF-97B2219B9A6CQ42988922-94234457-7B9D-4FB8-BEAE-735E8CB28C5AQ42992556-1AD7FB4B-826B-4E04-B6CF-BDE140ADCE65Q42992752-39FEBF11-7469-4E42-B0D0-4F5E42DF6BADQ42994765-EB1FE11B-3043-4961-9F70-42143A246D1DQ43032172-39D00C45-965E-46EC-AD86-6757157EF155Q43037910-C9AB2DF5-0191-4028-8A09-ECF556563D5DQ43041031-40F56A77-1D0A-4494-9403-7AD36070A2F1Q43047795-A1123E55-52F9-429A-A99E-3B7791599DDE
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Salvatore Petta
@ast
Salvatore Petta
@en
Salvatore Petta
@es
Salvatore Petta
@nl
Salvatore Petta
@sl
type
label
Salvatore Petta
@ast
Salvatore Petta
@en
Salvatore Petta
@es
Salvatore Petta
@nl
Salvatore Petta
@sl
prefLabel
Salvatore Petta
@ast
Salvatore Petta
@en
Salvatore Petta
@es
Salvatore Petta
@nl
Salvatore Petta
@sl
P106
P1153
11141625100
P21
P31
P496
0000-0002-0822-9673